TRIAL DETAIL
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Ipilimumab and Imatinib Mesylate in Advanced Cancer |
|||
NCT#: |
||||
Conditions: |
Advanced Cancer |
|||
Status: |
Active, not recruiting |
|||
Phase: |
1 |
Start Date 02/01/2013 |
Age of Trial (yrs) 11.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor + CTLA4 inhibitor |
|||
Strategy: |
Block KIT + Stimulate the immune system |
|||
Trial Type: |
Specifically GIST plus other cancers |
|||
Other Protocol IDs: |
2012-0784 |
|||
Sponsor: |
M.D. Anderson Cancer Center |
|||
Patient Contact: |
Contact: David S. Hong, MD 713-563-1930
dshong@mdanderson.org |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral
Intravenous |
|||
Trial Notes: |
Inclusion criteria state: "For dose escalation study, patients must have histological confirmation of solid tumors that is metastatic or unresectable. For expansion cohorts, patients must have metastatic or unresectable GIST, melanoma, or uncategorized tumors that are positive for c-KIT mutations. KIT positive tumors will be confirmed in original biopsied tumors and biopsied tumors acquired during this study." |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |